Literature DB >> 15865066

Identification of serum proteins related to adverse effects induced by docetaxel infusion from protein expression profiles of serum using SELDI ProteinChip system.

Yuji Heike1, Mami Hosokawa, Shozo Osumi, Daisuke Fujii, Kenjiro Aogi, Nagio Takigawa, Mikiko Ida, Hisao Tajiri, Kenji Eguchi, Mieko Shiwa, Rumi Wakatabe, Hisashi Arikuni, Yoichi Takaue, Shigemitsu Takashima.   

Abstract

BACKGROUND: For the development of quick and easy methods for screening and identifying treatment-responsive proteins, we determined the protein expression profile of the serum after docetaxel infusion using a surface-enhanced laser desorption/ionization time-of-flight mass spectroscopy (SELDI TOF-MS) system.
MATERIALS AND METHODS: Blood from breast cancer patients was collected before and 4, 8, 24 and 48 hours after docetaxel infusion. The protein expression profile was determined by a SELDI TOF-MS system. The relative expression levels of target proteins were compared during the time-course after docetaxel injection.
RESULTS: We identified two representative proteins with molecular weights of 7790 Da and 9285 Da. The 7790 Da protein was high molecular weight kininogen, and the 9285 Da protein was apolipoprotein A-II. These two proteins had similar expression patterns in 5 patients, except one patient who experienced severe, acute, adverse effects.
CONCLUSION: These results suggest that protein expression profiles determined by SELDI TOF-MS represent useful data for the identification of treatment-responsive proteins.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15865066

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

Review 1.  [Identification of biomarkers and therapeutic targets for renal cell cancer using ProteinChip technology].

Authors:  K Junker; F von Eggeling; J Müller; T Steiner; J Schubert
Journal:  Urologe A       Date:  2006-03       Impact factor: 0.639

Review 2.  Contributions of advanced proteomics technologies to cancer diagnosis.

Authors:  Sergio Ciordia; Vivian de Los Ríos; Juan-Pablo Albar
Journal:  Clin Transl Oncol       Date:  2006-08       Impact factor: 3.405

3.  Mass spectrometry-based serum proteome pattern analysis in molecular diagnostics of early stage breast cancer.

Authors:  Monika Pietrowska; Lukasz Marczak; Joanna Polanska; Katarzyna Behrendt; Elzbieta Nowicka; Anna Walaszczyk; Aleksandra Chmura; Regina Deja; Maciej Stobiecki; Andrzej Polanski; Rafal Tarnawski; Piotr Widlak
Journal:  J Transl Med       Date:  2009-07-13       Impact factor: 5.531

Review 4.  Breast tumor metastasis: analysis via proteomic profiling.

Authors:  Steve Goodison; Virginia Urquidi
Journal:  Expert Rev Proteomics       Date:  2008-06       Impact factor: 3.940

5.  Mass spectrometry-based analysis of therapy-related changes in serum proteome patterns of patients with early-stage breast cancer.

Authors:  Monika Pietrowska; Joanna Polanska; Lukasz Marczak; Katarzyna Behrendt; Elzbieta Nowicka; Maciej Stobiecki; Andrzej Polanski; Rafal Tarnawski; Piotr Widlak
Journal:  J Transl Med       Date:  2010-07-11       Impact factor: 5.531

6.  Clinical proteomics of breast cancer.

Authors:  Y Baskın; T Yiğitbaşı
Journal:  Curr Genomics       Date:  2010-11       Impact factor: 2.236

7.  A systems approach to clinical oncology: focus on breast cancer.

Authors:  Mark Abramovitz; Brian Leyland-Jones
Journal:  Proteome Sci       Date:  2006-04-04       Impact factor: 2.480

8.  Proteomics and mass spectrometry for cancer biomarker discovery.

Authors:  Ming Lu; Kym F Faull; Julian P Whitelegge; Jianbo He; Dejun Shen; Romaine E Saxton; Helena R Chang
Journal:  Biomark Insights       Date:  2007-10-03

9.  MALDI-MS-Based Profiling of Serum Proteome: Detection of Changes Related to Progression of Cancer and Response to Anticancer Treatment.

Authors:  Monika Pietrowska; Piotr Widłak
Journal:  Int J Proteomics       Date:  2012-07-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.